Sir Andrew Dillon, head of the body that approves drugs for the NHS, has hit back against claims by the pharmaceutical industry that he is blocking too many new medicines. The chief executive of NICE has strongly rejected accusations made by nine drug companies, including Pfizer, Novartis and Sanofi, that he focuses too much on cost cutting. The companies told the Telegraph that NICE’s processes are damaging the “health of the British public and the wealth of the British economy.”